BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

...pipelines, of which one other is part of a pharma-biotech partnership. Sanofi (Euronext:SAN; NASDAQ:SNY) and Denali...
...DNL788 emerged as the partners’ preferred candidate after early clinical work on RIPK1 inhibitor DNL747.The Sanofi-Denali...
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...Staff Writer Alzheimer’s disease immunotherapy reduces β-amyloid without increasing brain bleedingPublished in Science Translational Medicine, Denali...
...Compound #), PLX4032 (Compound #), vemurafenib (Generic) Victrelis, boceprevir (MK-3034, sch 503034) Incivek, Incivo, Telavic, telaprevir (MP-424, VX-950) Denali...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...a Neurodegeneration Consortium (NDC), a partnership with three other academic institutions that formed a collaboration with Denali...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...from the EV-201 trial showed tumor responses in patients ineligible for cisplatin chemotherapy.More data boost Denali’s...
...I/II study of ETV:IDS (DNL310) added to the early evidence that transport vehicle technology from Denali...
...in the cerebrospinal fluid of four out five patients with mucopolysaccharidosis II, or Hunter syndrome. Denali...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...risk alleles for ALS in RNA binding proteins. Denali...
...B.V. BrainStorm Cell Therapeutics Inc. Alexion Pharmaceuticals Inc. Neurimmune AG Accellix Inc. Denali...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...progress.In recent years, Arch Venture Partners has participated in nine-digit rounds for several biotechs, including neurodegeneration company Denali...
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

...for neuroscience indications: Alector Inc. (NASDAQ:ALEC), with AL002 in Phase I testing for Alzheimer’s disease, and Denali...
...receptor expressed on myeloid cells 2 (TREM2) Danielle Golovin AL002 DNL919 (ATV:TREM2) Atlas Venture Amgen Inc. Hatteras Venture Partners Alexandria Venture Investments Alector Inc. Denali...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...targeting LRRK2 from Biogen Inc. (NASDAQ:BIIB) and Denali...
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

...By selina koch, executive editor Denali this week...
...neurodegeneration and beyond,” said Denali CEO Ryan Watts.Denali...
...ERT that acts both peripherally and centrally. Denali...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

...and featured some of the biggest upfront payments made in the past five years.For example, Denali Therapeutics...
...Deal ”; “AZ Goes Early for its Latest $1B ADC Deal”). Amanda Micklus Biogen Inc. Daiichi Sankyo Co. Ltd. Denali...
Items per page:
1 - 10 of 122
BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

...pipelines, of which one other is part of a pharma-biotech partnership. Sanofi (Euronext:SAN; NASDAQ:SNY) and Denali...
...DNL788 emerged as the partners’ preferred candidate after early clinical work on RIPK1 inhibitor DNL747.The Sanofi-Denali...
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...Staff Writer Alzheimer’s disease immunotherapy reduces β-amyloid without increasing brain bleedingPublished in Science Translational Medicine, Denali...
...Compound #), PLX4032 (Compound #), vemurafenib (Generic) Victrelis, boceprevir (MK-3034, sch 503034) Incivek, Incivo, Telavic, telaprevir (MP-424, VX-950) Denali...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

...a Neurodegeneration Consortium (NDC), a partnership with three other academic institutions that formed a collaboration with Denali...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

...from the EV-201 trial showed tumor responses in patients ineligible for cisplatin chemotherapy.More data boost Denali’s...
...I/II study of ETV:IDS (DNL310) added to the early evidence that transport vehicle technology from Denali...
...in the cerebrospinal fluid of four out five patients with mucopolysaccharidosis II, or Hunter syndrome. Denali...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...risk alleles for ALS in RNA binding proteins. Denali...
...B.V. BrainStorm Cell Therapeutics Inc. Alexion Pharmaceuticals Inc. Neurimmune AG Accellix Inc. Denali...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...progress.In recent years, Arch Venture Partners has participated in nine-digit rounds for several biotechs, including neurodegeneration company Denali...
BioCentury | Dec 17, 2020
Emerging Company Profile

Vigil: restoring the vigilance of microglia

...for neuroscience indications: Alector Inc. (NASDAQ:ALEC), with AL002 in Phase I testing for Alzheimer’s disease, and Denali...
...receptor expressed on myeloid cells 2 (TREM2) Danielle Golovin AL002 DNL919 (ATV:TREM2) Atlas Venture Amgen Inc. Hatteras Venture Partners Alexandria Venture Investments Alector Inc. Denali...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...targeting LRRK2 from Biogen Inc. (NASDAQ:BIIB) and Denali...
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

...By selina koch, executive editor Denali this week...
...neurodegeneration and beyond,” said Denali CEO Ryan Watts.Denali...
...ERT that acts both peripherally and centrally. Denali...
BioCentury | Sep 11, 2020
Deals

Data Bytes: upfront tally shows 2020’s dealmakers playing catch-up

...and featured some of the biggest upfront payments made in the past five years.For example, Denali Therapeutics...
...Deal ”; “AZ Goes Early for its Latest $1B ADC Deal”). Amanda Micklus Biogen Inc. Daiichi Sankyo Co. Ltd. Denali...
Items per page:
1 - 10 of 122